1
|
Böhm S, Woudenberg T, Stark K, Böhmer MM, Katz K, Kuhnert R, Schlaud M, Wilking H, Fingerle V. Seroprevalence, seroconversion and seroreversion of Borrelia burgdorferi-specific IgG antibodies in two population-based studies in children and adolescents, Germany, 2003 to 2006 and 2014 to 2017. Euro Surveill 2023; 28:2200855. [PMID: 37616114 PMCID: PMC10451011 DOI: 10.2807/1560-7917.es.2023.28.34.2200855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2022] [Accepted: 05/09/2023] [Indexed: 08/25/2023] Open
Abstract
BackgroundLyme borreliosis (LB), caused by Borrelia burgdorferi (Bb), is the most common tick-borne infection in Germany. Antibodies against Bb are prevalent in the general population but information on temporal changes of prevalence and estimates of seroconversion (seroincidence) and seroreversion are lacking, especially for children and adolescents.AimWe aimed at assessing antibodies against Bb and factors associated with seropositivity in children and adolescents in Germany.MethodsWe estimated seroprevalence via two consecutive cross-sectional surveys (2003-2006 and 2014-2017). Based on a longitudinal survey component, we estimated annual seroconversion/seroreversion rates.ResultsSeroprevalence was 4.4% (95% confidence interval (CI): 3.9-4.9%) from 2003 to 2006 and 4.1% (95% CI: 3.2-5.1%) from 2014 to 2017. Seroprevalence increased with age, was higher in male children, the south-eastern regions of Germany and among those with a high socioeconomic status. The annual seroconversion rate was 0.3% and the annual seroreversion rate 3.9%. Males were more likely to seroconvert compared with females. Low antibody levels were the main predictor of seroreversion.ConclusionWe did not detect a change in seroprevalence in children and adolescents in Germany over a period of 11 years. Potential long-term changes, for example due to climatic changes, need to be assessed in consecutive serosurveys. Seroconversion was more likely among children and adolescents than among adults, representing a target group for preventive measures. Seroreversion rates are over twice as high in children and adolescents compared with previous studies among adults. Thus, seroprevalence estimates and seroconversion rates in children are likely underestimated.
Collapse
Affiliation(s)
- Stefanie Böhm
- Bavarian Health and Food Safety Authority, Munich, Germany
- Postgraduate Training for Applied Epidemiology (PAE), Robert Koch Institute, Berlin, Germany
- ECDC Fellowship Programme, Field Epidemiology Path (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
| | - Tom Woudenberg
- Bavarian Health and Food Safety Authority, Munich, Germany
- ECDC Fellowship Programme, Field Epidemiology Path (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
- Infectious Disease Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Paris, France
| | - Klaus Stark
- Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany
| | - Merle M Böhmer
- Bavarian Health and Food Safety Authority, Munich, Germany
- Institute of Social Medicine and Health Systems Research, Otto-von-Guericke-University, Magdeburg, Germany
| | - Katharina Katz
- Bavarian Health and Food Safety Authority, Munich, Germany
| | - Ronny Kuhnert
- Department for Epidemiology and Health Monitoring, Robert Koch Institute, Berlin, Germany
| | - Martin Schlaud
- Department for Epidemiology and Health Monitoring, Robert Koch Institute, Berlin, Germany
| | - Hendrik Wilking
- Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany
- These authors contributed equally to the work and share the last authorship
| | - Volker Fingerle
- Bavarian Health and Food Safety Authority, Munich, Germany
- German National Reference Centre for Borrelia, Oberschleißheim, Germany
- These authors contributed equally to the work and share the last authorship
| |
Collapse
|
2
|
De Thoisy A, Woudenberg T, Pelleau S, Donnadieu F, Garcia L, Pinaud L, Tondeur L, Meola A, Arowas L, Clement N, Backovic M, Ungeheuer MN, Fontanet A, White M. Seroepidemiology of the Seasonal Human Coronaviruses NL63, 229E, OC43 and HKU1 in France. Open Forum Infect Dis 2023; 10:ofad340. [PMID: 37496603 PMCID: PMC10368309 DOI: 10.1093/ofid/ofad340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Accepted: 06/30/2023] [Indexed: 07/28/2023] Open
Abstract
Background The seasonal human coronaviruses (HCoV) NL63, 229E, OC43, and HKU1 are globally endemic, yet the majority of HCoV infections remain undiagnosed. Methods In a cross-sectional study, 2389 serum samples were collected from children and adults in France in 2020. In a longitudinal cohort study, 2520 samples were collected from 898 French individuals followed up between 2020 and 2021. Antibodies to HCoVs were measured using a bead-based multiplex assay. Results The rate of waning of anti-HCoV spike immunoglobulin G antibodies was estimated as 0.22-0.47 year-1 for children, and 0.13-0.27 year-1 for adults. Seroreversion was estimated as 0.31-1.37 year-1 in children and 0.19-0.72 year-1 in adults. The estimated seroconversion rate in children was consistent with 20%-39% of children being infected every year with each HCoV. Conclusions The high force of infection in children indicates that HCoVs may be responsible for a substantial proportion of fever episodes experienced by children.
Collapse
Affiliation(s)
- Alix De Thoisy
- Infectious Disease Epidemiology and Analytics G5 Unit, Department of Global Health, Institut Pasteur, Université Paris Cité, Paris, France
| | - Tom Woudenberg
- Infectious Disease Epidemiology and Analytics G5 Unit, Department of Global Health, Institut Pasteur, Université Paris Cité, Paris, France
| | - Stéphane Pelleau
- Correspondence: Michael White, PhD, Infectious Disease Epidemiology and Analytics G5 Unit, Department of Global Health, Institut Pasteur, Rue du Docteur Roux, Paris 75015, France (); Stéphane Pelleau, PhD, Infectious Disease Epidemiology and Analytics G5 Unit, Department of Global Health, Institut Pasteur, Rue du Docteur Roux, Paris 75015, France ()
| | - Françoise Donnadieu
- Infectious Disease Epidemiology and Analytics G5 Unit, Department of Global Health, Institut Pasteur, Université Paris Cité, Paris, France
| | - Laura Garcia
- Infectious Disease Epidemiology and Analytics G5 Unit, Department of Global Health, Institut Pasteur, Université Paris Cité, Paris, France
| | - Laurie Pinaud
- Epidemiology of Emerging Diseases Unit, Department of Global Health, Institut Pasteur, Université Paris Cité, Paris, France
| | - Laura Tondeur
- Epidemiology of Emerging Diseases Unit, Department of Global Health, Institut Pasteur, Université Paris Cité, Paris, France
| | - Annalisa Meola
- Structural Virology Unit, Department of Virology and CNRS UMR 3569, Institut Pasteur, Université Paris Cité, Paris, France
| | - Laurence Arowas
- Investigation Clinique et Accès aux Ressources Biologiques (ICAReB), Center for Translational Research, Institut Pasteur, Paris, France
| | - Nathalie Clement
- Coordination Clinique du CRT, Center for Translational Research, Institut Pasteur, Paris, France
| | - Marija Backovic
- Structural Virology Unit, Department of Virology and CNRS UMR 3569, Institut Pasteur, Université Paris Cité, Paris, France
| | - Marie-Noëlle Ungeheuer
- Investigation Clinique et Accès aux Ressources Biologiques (ICAReB), Center for Translational Research, Institut Pasteur, Paris, France
| | - Arnaud Fontanet
- Epidemiology of Emerging Diseases Unit, Department of Global Health, Institut Pasteur, Université Paris Cité, Paris, France
- PACRI Unit, Conservatoire National des Arts et Métiers, Paris, France
| | - Michael White
- Correspondence: Michael White, PhD, Infectious Disease Epidemiology and Analytics G5 Unit, Department of Global Health, Institut Pasteur, Rue du Docteur Roux, Paris 75015, France (); Stéphane Pelleau, PhD, Infectious Disease Epidemiology and Analytics G5 Unit, Department of Global Health, Institut Pasteur, Rue du Docteur Roux, Paris 75015, France ()
| | | |
Collapse
|
3
|
Gavilán AM, van de Nes-Reijnen L, Castellanos A, Woudenberg T, López-Perea N, Masa-Calles J, Echevarría JE, Fernández-García A, Bodewes R. Comparison of circulation patterns of mumps virus in the Netherlands and Spain (2015-2020). Front Microbiol 2023; 14:1207500. [PMID: 37396375 PMCID: PMC10311905 DOI: 10.3389/fmicb.2023.1207500] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2023] [Accepted: 05/22/2023] [Indexed: 07/04/2023] Open
Abstract
Background Mumps is a viral infection mainly characterized by inflammation of the parotid glands. Despite of vaccination programs, infections among fully vaccinated populations were reported. The World Health Organization (WHO) recommends molecular surveillance of mumps based on sequencing of the small hydrophobic (SH) gene. The use of hypervariable non-coding regions (NCR) as additional molecular markers was proposed in multiple studies. Circulation of mumps virus (MuV) genotypes and variants in different European countries were described in the literature. From 2010 to 2020, mumps outbreaks caused by genotype G were described. However, this issue has not been analyzed from a wider geographical perspective. In the present study, sequence data from MuV detected in Spain and in The Netherlands during a period of 5 years (2015- March 2020) were analyzed to gain insights in the spatiotemporal spread of MuV at a larger geographical scale than in previous local studies. Methods A total of 1,121 SH and 262 NCR between the Matrix and Fusion protein genes (MF-NCR) sequences from both countries were included in this study. Analysis of SH revealed 106 different haplotypes (set of identical sequences). Results Of them, seven showing extensive circulation were considered variants. All seven were detected in both countries in coincident temporal periods. A single MF-NCR haplotype was detected in 156 sequences (59.3% of total), and was shared by five of the seven SH variants, as well as three minor MF-NCR haplotypes. All SH variants and MF-NCR haplotypes shared by both countries were detected first in Spain. Discussion Our results suggest a transmission way from south to north Europe. The higher incidence rate of mumps in Spain in spite of similar immunization coverage in both countries, could be associated with higher risk of MuV exportation. In conclusion, the present study provided novel insights into the circulation of MuV variants and haplotypes beyond the borders of single countries. In fact, the use of MF-NCR molecular tool allowed to reveal MuV transmission flows between The Netherlands and Spain. Similar studies including other (European) countries are needed to provide a broader view of the data presented in this study.
Collapse
Affiliation(s)
- Ana M. Gavilán
- Centro Nacional de Microbiología (CNM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- CIBER de Epidemiología y Salud Pública (CIBERESP), ISCIII, Madrid, Spain
| | - Linda van de Nes-Reijnen
- Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands
| | - Ana Castellanos
- Centro Nacional de Microbiología (CNM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- CIBER de Epidemiología y Salud Pública (CIBERESP), ISCIII, Madrid, Spain
| | - Tom Woudenberg
- Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands
| | - Noemí López-Perea
- CIBER de Epidemiología y Salud Pública (CIBERESP), ISCIII, Madrid, Spain
- Centro Nacional de Epidemiología, Instituto de Salud Carlos III (ISCIII), Madrid, Spain
| | - Josefa Masa-Calles
- CIBER de Epidemiología y Salud Pública (CIBERESP), ISCIII, Madrid, Spain
- Centro Nacional de Epidemiología, Instituto de Salud Carlos III (ISCIII), Madrid, Spain
| | - Juan E. Echevarría
- Centro Nacional de Microbiología (CNM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- CIBER de Epidemiología y Salud Pública (CIBERESP), ISCIII, Madrid, Spain
| | - Aurora Fernández-García
- Centro Nacional de Microbiología (CNM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- CIBER de Epidemiología y Salud Pública (CIBERESP), ISCIII, Madrid, Spain
| | - Rogier Bodewes
- Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands
| |
Collapse
|
4
|
Woudenberg T, Pinaud L, Garcia L, Tondeur L, Pelleau S, De Thoisy A, Donnadieu F, Backovic M, Attia M, Hozé N, Duru C, Koffi AD, Castelain S, Ungeheuer MN, Fernandes Pellerin S, Planas D, Bruel T, Cauchemez S, Schwartz O, Fontanet A, White M. Estimated protection against COVID-19 based on predicted neutralisation titres from multiple antibody measurements in a longitudinal cohort, France, April 2020 to November 2021. Euro Surveill 2023; 28:2200681. [PMID: 37347417 PMCID: PMC10288827 DOI: 10.2807/1560-7917.es.2023.28.25.2200681] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2022] [Accepted: 03/28/2023] [Indexed: 06/23/2023] Open
Abstract
BackgroundThe risk of SARS-CoV-2 (re-)infection remains present given waning of vaccine-induced and infection-acquired immunity, and ongoing circulation of new variants.AimTo develop a method that predicts virus neutralisation and disease protection based on variant-specific antibody measurements to SARS-CoV-2 antigens.MethodsTo correlate antibody and neutralisation titres, we collected 304 serum samples from individuals with either vaccine-induced or infection-acquired SARS-CoV-2 immunity. Using the association between antibody and neutralisation titres, we developed a prediction model for SARS-CoV-2-specific neutralisation titres. From predicted neutralising titres, we inferred protection estimates to symptomatic and severe COVID-19 using previously described relationships between neutralisation titres and protection estimates. We estimated population immunity in a French longitudinal cohort of 905 individuals followed from April 2020 to November 2021.ResultsWe demonstrated a strong correlation between anti-SARS-CoV-2 antibodies measured using a low cost high-throughput assay and antibody response capacity to neutralise live virus. Participants with a single vaccination or immunity caused by infection were especially vulnerable to symptomatic or severe COVID-19. While the median reduced risk of COVID-19 from Delta variant infection in participants with three vaccinations was 96% (IQR: 94-98), median reduced risk among participants with infection-acquired immunity was only 42% (IQR: 22-66).ConclusionOur results are consistent with data from vaccine effectiveness studies, indicating the robustness of our approach. Our multiplex serological assay can be readily adapted to study new variants and provides a framework for development of an assay that would include protection estimates.
Collapse
Affiliation(s)
- Tom Woudenberg
- Infectious Disease Epidemiology and Analytics G5 Unit, Department of Global Health, Institut Pasteur, Université Paris-Cité, Paris, France
| | - Laurie Pinaud
- Emerging Diseases Epidemiology Unit, Institut Pasteur, Université Paris-Cité, Paris, France
| | - Laura Garcia
- Infectious Disease Epidemiology and Analytics G5 Unit, Department of Global Health, Institut Pasteur, Université Paris-Cité, Paris, France
| | - Laura Tondeur
- Emerging Diseases Epidemiology Unit, Institut Pasteur, Université Paris-Cité, Paris, France
| | - Stéphane Pelleau
- Infectious Disease Epidemiology and Analytics G5 Unit, Department of Global Health, Institut Pasteur, Université Paris-Cité, Paris, France
| | - Alix De Thoisy
- Infectious Disease Epidemiology and Analytics G5 Unit, Department of Global Health, Institut Pasteur, Université Paris-Cité, Paris, France
| | - Françoise Donnadieu
- Infectious Disease Epidemiology and Analytics G5 Unit, Department of Global Health, Institut Pasteur, Université Paris-Cité, Paris, France
| | - Marija Backovic
- Structural Virology Unit, Department of Virology and CNRS UMR 3569, Institut Pasteur, Université Paris-Cité, Paris, France
| | - Mikaël Attia
- Molecular Genetics of RNA Viruses, Department of Virology, Institut Pasteur, Université Paris-Cité, CNRS UMR 3569, Paris, France
| | - Nathanael Hozé
- Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, Université Paris-Cité, UMR2000, CNRS, Paris, France
| | - Cécile Duru
- Hôpital de Crépy-en-Valois, Crépy-en-Valois, France
| | | | | | - Marie-Noelle Ungeheuer
- Clinical Investigation and Access to Research Bioresources (ICAReB) platform, Center for Translational Science, Institut Pasteur, Paris, France
| | | | - Delphine Planas
- Virus and Immunity Unit, Department of Virology, Institut Pasteur, Université Paris-Cité, Paris, France
| | - Timothée Bruel
- Virus and Immunity Unit, Department of Virology, Institut Pasteur, Université Paris-Cité, Paris, France
| | - Simon Cauchemez
- Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, Université Paris-Cité, UMR2000, CNRS, Paris, France
| | - Olivier Schwartz
- Virus and Immunity Unit, Department of Virology, Institut Pasteur, Université Paris-Cité, Paris, France
| | - Arnaud Fontanet
- PACRI Unit, Conservatoire National des Arts et Métiers, Paris, France
- Emerging Diseases Epidemiology Unit, Institut Pasteur, Université Paris-Cité, Paris, France
| | - Michael White
- Infectious Disease Epidemiology and Analytics G5 Unit, Department of Global Health, Institut Pasteur, Université Paris-Cité, Paris, France
| |
Collapse
|
5
|
Bruel T, Pinaud L, Tondeur L, Planas D, Staropoli I, Porrot F, Guivel-Benhassine F, Attia M, Pelleau S, Woudenberg T, Duru C, Koffi AD, Castelain S, Fernandes-Pellerin S, Jolly N, De Facci LP, Roux E, Ungeheuer MN, Van Der Werf S, White M, Schwartz O, Fontanet A. Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study. EClinicalMedicine 2022; 51:101576. [PMID: 35891947 PMCID: PMC9307278 DOI: 10.1016/j.eclinm.2022.101576] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/05/2022] [Revised: 07/01/2022] [Accepted: 07/04/2022] [Indexed: 11/23/2022] Open
Abstract
BACKGROUND The protective immunity against omicron following a BNT162b2 Pfizer booster dose among elderly individuals (ie, those aged >65 years) is not well characterised. METHODS In a community-based, prospective, longitudinal cohort study taking place in France in which 75 residents from three nursing homes were enrolled, we selected 38 residents who had received a two-dose regimen of mRNA vaccine and a booster dose of Pfizer BNT162b2 vaccine. We excluded individuals that did not receive three vaccine doses or did not have available sera samples. We measured anti-S IgG antibodies and neutralisation capacity in sera taken 56 (28-68) and 55 (48-64) days (median (range)) after the 2nd and 3rd vaccine doses, respectively. Antibodies targeting the SARS-CoV-2 Spike protein were measured with the S-Flow assay as binding antibody units per milliliter (BAU/mL). Neutralising activities in sera were measured as effective dilution 50% (ED50) with the S-Fuse assay using authentic isolates of delta and omicron BA.1. FINDINGS Among the 38 elderly individuals recruited to the cohort study between November 23rd, 2020 and April 29th, 2021, with median age of 88 (range 72-101) years, 30 (78.95%) had been previously infected with SARS-CoV-2. After three vaccine doses, serum neutralising activity was lower against omicron BA.1 (median ED50 of 774.5, range 15.0-34660.0) than the delta variant (median ED50 of 4972.0, range 213.7-66340.0), and higher among previously infected (ie, convalescent; median ED50 against omicron: 1088.0, range 32.6-34660.0) compared with infection-naive residents (median ED50 against omicron: 188.4, range 15.0-8918.0). During the French omicron wave in December 2021-January 2022, 75% (6/8) of naive residents were infected, compared to 25% (7/30) of convalescent residents (P=0.0114). Anti-Spike antibody levels and neutralising activity against omicron BA.1 after a third BNT162b2 booster dose were lower in those with breakthrough BA.1 infection (n=13) compared with those without (n=25), with a median of 1429.9 (range 670.9-3818.3) BAU/mL vs 2528.3 (range 695.4-8832.0) BAU/mL (P=0.029) and a median ED50 of 281.1 (range 15.0-2136.0) vs 1376.0 (range 32.6-34660.0) (P=0.0013), respectively. INTERPRETATION This study shows that elderly individuals who received three vaccine doses elicit neutralising antibodies against the omicron BA.1 variant of SARS-CoV-2. Elderly individuals who had also been previously infected showed higher neutralising activity compared with naive individuals. Yet, breakthrough infections with omicron occurred. Individuals with breakthrough infections had significantly lower neutralising titers compared to individuals without breakthrough infection. Thus, a fourth dose of vaccine may be useful in the elderly population to increase the level of neutralising antibodies and compensate for waning immunity. FUNDING Institut Pasteur, Fondation pour la Recherche Médicale (FRM), European Health Emergency Preparedness and Response Authority (HERA), Agence nationale de recherches sur le sida et les hépatites virales - Maladies Infectieuses Emergentes (ANRS-MIE), Agence nationale de la recherche (ANR), Assistance Publique des Hôpitaux de Paris (AP-HP) and Fondation de France.
Collapse
Affiliation(s)
- Timothée Bruel
- Virus & Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR 3569, Paris, France
- Vaccine Research Institute, Créteil, France
- Corresponding author at: Unité Virus et Immunité, Institut Pasteur, 25-28 Rue du docteur Roux, 75015 Paris, France.
| | - Laurie Pinaud
- Emerging Diseases Epidemiology Unit, Institut Pasteur, Université Paris Cité, Paris, France
| | - Laura Tondeur
- Emerging Diseases Epidemiology Unit, Institut Pasteur, Université Paris Cité, Paris, France
| | - Delphine Planas
- Virus & Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR 3569, Paris, France
- Vaccine Research Institute, Créteil, France
| | - Isabelle Staropoli
- Virus & Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR 3569, Paris, France
| | - Françoise Porrot
- Virus & Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR 3569, Paris, France
| | | | - Mikaël Attia
- Molecular Genetics of RNA Viruses Unit, Institut Pasteur, Université Paris Cité, Paris, France
| | - Stéphane Pelleau
- Infectious Disease Epidemiology and Analytics Unit, Institut Pasteur, Université Paris Cité, Paris, France
| | - Tom Woudenberg
- Infectious Disease Epidemiology and Analytics Unit, Institut Pasteur, Université Paris Cité, Paris, France
| | - Cécile Duru
- Hôpital de Crépy-en-Valois, Crépy-en-Valois, France
| | | | | | | | - Nathalie Jolly
- Centre for Translational Science, Institut Pasteur, Paris, France
| | - Louise Perrin De Facci
- Clinical Investigation and access to bioresources (ICAReB) platform, Centre for Translational Science, Institut Pasteur, Paris, France
| | - Emmanuel Roux
- Clinical Investigation and access to bioresources (ICAReB) platform, Centre for Translational Science, Institut Pasteur, Paris, France
| | - Marie-Noëlle Ungeheuer
- Clinical Investigation and access to bioresources (ICAReB) platform, Centre for Translational Science, Institut Pasteur, Paris, France
| | - Sylvie Van Der Werf
- Molecular Genetics of RNA Viruses Unit, Institut Pasteur, Université Paris Cité, Paris, France
| | - Michael White
- Infectious Disease Epidemiology and Analytics Unit, Institut Pasteur, Université Paris Cité, Paris, France
| | - Olivier Schwartz
- Virus & Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR 3569, Paris, France
- Vaccine Research Institute, Créteil, France
| | - Arnaud Fontanet
- Emerging Diseases Epidemiology Unit, Institut Pasteur, Université Paris Cité, Paris, France
- Conservatoire National des Arts et Métiers, PACRI Unit, Paris, France
- Corresponding author at: Emerging Diseases Epidemiology Unit, Institut Pasteur, 25-28 Rue du docteur Roux, 75015 Paris, France.
| |
Collapse
|
6
|
Garcia L, Woudenberg T, Rosado J, Dyer AH, Donnadieu F, Planas D, Bruel T, Schwartz O, Prazuck T, Velay A, Fafi-Kremer S, Batten I, Reddy C, Connolly E, McElheron M, Kennelly SP, Bourke NM, White MT, Pelleau S. Kinetics of the SARS-CoV-2 Antibody Avidity Response Following Infection and Vaccination. Viruses 2022; 14:v14071491. [PMID: 35891471 PMCID: PMC9321390 DOI: 10.3390/v14071491] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2022] [Revised: 06/29/2022] [Accepted: 07/06/2022] [Indexed: 12/04/2022] Open
Abstract
Serological assays capable of measuring antibody responses induced by previous infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been critical tools in the response to the COVID-19 pandemic. In this study, we use bead-based multiplex assays to measure IgG and IgA antibodies and IgG avidity to five SARS-CoV-2 antigens (Spike (S), receptor-binding domain (RBD), Nucleocapsid (N), S subunit 2, and Membrane-Envelope fusion (ME)). These assays were performed in several cohorts of healthcare workers and nursing home residents, who were followed for up to eleven months after SARS-CoV-2 infection or up to six months after vaccination. Our results show distinct kinetic patterns of antibody quantity (IgG and IgA) and avidity. While IgG and IgA antibody levels waned over time, with IgA antibody levels waning more rapidly, avidity increased with time after infection or vaccination. These contrasting kinetic patterns allow for the estimation of time since previous SARS-CoV-2 infection. Including avidity measurements in addition to antibody levels in a classification algorithm for estimating time since infection led to a substantial improvement in accuracy, from 62% to 78%. The inclusion of antibody avidity in panels of serological assays can yield valuable information for improving serosurveillance during SARS-CoV-2 epidemics.
Collapse
Affiliation(s)
- Laura Garcia
- Infectious Diseases Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Université Paris Cité, 75015 Paris, France; (L.G.); (T.W.); (J.R.); (F.D.)
| | - Tom Woudenberg
- Infectious Diseases Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Université Paris Cité, 75015 Paris, France; (L.G.); (T.W.); (J.R.); (F.D.)
| | - Jason Rosado
- Infectious Diseases Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Université Paris Cité, 75015 Paris, France; (L.G.); (T.W.); (J.R.); (F.D.)
| | - Adam H. Dyer
- Tallaght University Hospital, Tallaght, D24 NR0A Dublin, Ireland; (A.H.D.); (S.P.K.)
- Department of Medical Gerontology, School of Medicine, Trinity College Dublin, D02 PN40 Dublin, Ireland; (I.B.); (C.R.); (E.C.); (M.M.); (N.M.B.)
| | - Françoise Donnadieu
- Infectious Diseases Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Université Paris Cité, 75015 Paris, France; (L.G.); (T.W.); (J.R.); (F.D.)
| | - Delphine Planas
- Virus & Immunity Unit, Department of Virology, Institut Pasteur, Université Paris Cité, 75015 Paris, France; (D.P.); (T.B.); (O.S.)
| | - Timothée Bruel
- Virus & Immunity Unit, Department of Virology, Institut Pasteur, Université Paris Cité, 75015 Paris, France; (D.P.); (T.B.); (O.S.)
| | - Olivier Schwartz
- Virus & Immunity Unit, Department of Virology, Institut Pasteur, Université Paris Cité, 75015 Paris, France; (D.P.); (T.B.); (O.S.)
| | - Thierry Prazuck
- CHR d’Orléans, Service de Maladies Infectieuses, 45100 Orléans, France;
| | - Aurélie Velay
- CHU de Strasbourg, Laboratoire de Virologie, CEDEX, 67091 Strasbourg, France; (A.V.); (S.F.-K.)
- Unité Mixte de Recherche Scientifique Immuno-Rhumathologie Moléculaire (IRM UMR-S) 1109, Strasbourg University, Institut National de la Santé et de la Recherche Médicale (INSERM), CEDEX, 67084 Strasbourg, France
| | - Samira Fafi-Kremer
- CHU de Strasbourg, Laboratoire de Virologie, CEDEX, 67091 Strasbourg, France; (A.V.); (S.F.-K.)
- Unité Mixte de Recherche Scientifique Immuno-Rhumathologie Moléculaire (IRM UMR-S) 1109, Strasbourg University, Institut National de la Santé et de la Recherche Médicale (INSERM), CEDEX, 67084 Strasbourg, France
| | - Isabella Batten
- Department of Medical Gerontology, School of Medicine, Trinity College Dublin, D02 PN40 Dublin, Ireland; (I.B.); (C.R.); (E.C.); (M.M.); (N.M.B.)
| | - Conor Reddy
- Department of Medical Gerontology, School of Medicine, Trinity College Dublin, D02 PN40 Dublin, Ireland; (I.B.); (C.R.); (E.C.); (M.M.); (N.M.B.)
| | - Emma Connolly
- Department of Medical Gerontology, School of Medicine, Trinity College Dublin, D02 PN40 Dublin, Ireland; (I.B.); (C.R.); (E.C.); (M.M.); (N.M.B.)
| | - Matt McElheron
- Department of Medical Gerontology, School of Medicine, Trinity College Dublin, D02 PN40 Dublin, Ireland; (I.B.); (C.R.); (E.C.); (M.M.); (N.M.B.)
| | - Sean P. Kennelly
- Tallaght University Hospital, Tallaght, D24 NR0A Dublin, Ireland; (A.H.D.); (S.P.K.)
- Department of Medical Gerontology, School of Medicine, Trinity College Dublin, D02 PN40 Dublin, Ireland; (I.B.); (C.R.); (E.C.); (M.M.); (N.M.B.)
| | - Nollaig M. Bourke
- Department of Medical Gerontology, School of Medicine, Trinity College Dublin, D02 PN40 Dublin, Ireland; (I.B.); (C.R.); (E.C.); (M.M.); (N.M.B.)
| | - Michael T. White
- Infectious Diseases Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Université Paris Cité, 75015 Paris, France; (L.G.); (T.W.); (J.R.); (F.D.)
- Correspondence: (M.T.W.); (S.P.)
| | - Stéphane Pelleau
- Infectious Diseases Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Université Paris Cité, 75015 Paris, France; (L.G.); (T.W.); (J.R.); (F.D.)
- Correspondence: (M.T.W.); (S.P.)
| |
Collapse
|
7
|
Talla C, Loucoubar C, Roka JL, Barry MA, Ndiaye S, Diarra M, Thiam MS, Faye O, Dia M, Diop M, Ndiaye O, Tall A, Faye R, Mbow AA, Diouf B, Diallo JP, Keita IM, Ndiaye M, Woudenberg T, White M, Ting J, Diagne CT, Pasi O, Diop B, Sall AA, Vigan-Womas I, Faye O. Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020. IJID Reg 2022; 3:117-125. [PMID: 35720135 PMCID: PMC8897837 DOI: 10.1016/j.ijregi.2022.02.007] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/18/2021] [Revised: 02/16/2022] [Accepted: 02/17/2022] [Indexed: 11/17/2022]
Abstract
Objectives A nationwide cross-sectional epidemiological survey was conducted to capture the true extent of coronavirus disease 2019 (COVID-19) exposure in Senegal. Methods Multi-stage random cluster sampling of households was performed between October and November 2020, at the end of the first wave of COVID-19 transmission. Anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies were screened using three distinct ELISA assays. Adjusted prevalence rates for the survey design were calculated for each test separately, and thereafter combined. Crude and adjusted prevalence rates based on test performance were estimated to assess the seroprevalence. As some samples were collected in high malaria endemic areas, the relationship between SARS-CoV-2 seroreactivity and antimalarial humoral immunity was also investigated. Results Of the 1463 participants included in this study, 58.8% were female and 41.2% were male; their mean age was 29.2 years (range 0.20-84.8.0 years). The national seroprevalence was estimated at 28.4% (95% confidence interval 26.1-30.8%). There was substantial regional variability. All age groups were impacted, and the prevalence of SARS-CoV-2 was comparable in the symptomatic and asymptomatic groups. An estimated 4 744 392 (95% confidence interval 4 360 164-5 145 327) were potentially infected with SARS-CoV-2 in Senegal, while 16 089 COVID-19 RT-PCR laboratory-confirmed cases were reported by the national surveillance. No correlation was found between SARS-CoV-2 and Plasmodium seroreactivity. Conclusions These results provide a better estimate of SARS-CoV-2 dissemination in the Senegalese population. Preventive and control measures need to be reinforced in the country and especially in the south border regions.
Collapse
Affiliation(s)
- Cheikh Talla
- Epidemiology, Clinical Research and Data Sciences Department, Institut Pasteur de Dakar, Dakar, Senegal
| | - Cheikh Loucoubar
- Epidemiology, Clinical Research and Data Sciences Department, Institut Pasteur de Dakar, Dakar, Senegal
| | - Jerlie Loko Roka
- Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA
| | - Mamadou A. Barry
- Epidemiology, Clinical Research and Data Sciences Department, Institut Pasteur de Dakar, Dakar, Senegal
| | - Seynabou Ndiaye
- Epidemiology, Clinical Research and Data Sciences Department, Institut Pasteur de Dakar, Dakar, Senegal
| | - Maryam Diarra
- Epidemiology, Clinical Research and Data Sciences Department, Institut Pasteur de Dakar, Dakar, Senegal
| | - Mareme Seye Thiam
- Epidemiology, Clinical Research and Data Sciences Department, Institut Pasteur de Dakar, Dakar, Senegal
| | - Oumar Faye
- Virology Department, Institut Pasteur de Dakar, Dakar, Senegal
| | - Moussa Dia
- Virology Department, Institut Pasteur de Dakar, Dakar, Senegal
| | - Mamadou Diop
- Epidemiology, Clinical Research and Data Sciences Department, Institut Pasteur de Dakar, Dakar, Senegal
| | - Oumar Ndiaye
- Virology Department, Institut Pasteur de Dakar, Dakar, Senegal
| | - Adama Tall
- Epidemiology, Clinical Research and Data Sciences Department, Institut Pasteur de Dakar, Dakar, Senegal
| | - Rokhaya Faye
- Immunophysiopathology and Infectious Diseases Department, Institut Pasteur de Dakar, Dakar, Senegal
| | - Adji Astou Mbow
- Immunophysiopathology and Infectious Diseases Department, Institut Pasteur de Dakar, Dakar, Senegal
| | - Babacar Diouf
- Immunophysiopathology and Infectious Diseases Department, Institut Pasteur de Dakar, Dakar, Senegal
| | - Jean Pierre Diallo
- Prevention Department, Surveillance Division, Ministry of Health and Social Action, Dakar, Senegal
| | - Ibrahima Mamby Keita
- Prevention Department, Surveillance Division, Ministry of Health and Social Action, Dakar, Senegal
| | - Mamadou Ndiaye
- Prevention Department, Surveillance Division, Ministry of Health and Social Action, Dakar, Senegal
| | - Tom Woudenberg
- Malaria: Parasites and Hosts Unit, Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France
| | - Michael White
- Malaria: Parasites and Hosts Unit, Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France
| | - Jim Ting
- Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA
| | | | - Omer Pasi
- Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA
| | - Boly Diop
- Prevention Department, Surveillance Division, Ministry of Health and Social Action, Dakar, Senegal
| | - Amadou A. Sall
- Virology Department, Institut Pasteur de Dakar, Dakar, Senegal
| | - Inès Vigan-Womas
- Immunophysiopathology and Infectious Diseases Department, Institut Pasteur de Dakar, Dakar, Senegal
| | - Ousmane Faye
- Virology Department, Institut Pasteur de Dakar, Dakar, Senegal
| |
Collapse
|
8
|
Pelleau S, Woudenberg T, Rosado J, Donnadieu F, Garcia L, Obadia T, Gardais S, Elgharbawy Y, Velay A, Gonzalez M, Nizou JY, Khelil N, Zannis K, Cockram C, Merkling SH, Meola A, Kerneis S, Terrier B, de Seze J, Planas D, Schwartz O, Dejardin F, Petres S, von Platen C, Pellerin SF, Arowas L, de Facci LP, Duffy D, Cheallaigh CN, Dunne J, Conlon N, Townsend L, Duong V, Auerswald H, Pinaud L, Tondeur L, Backovic M, Hoen B, Fontanet A, Mueller I, Fafi-Kremer S, Bruel T, White M. Kinetics of the Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and Serological Estimation of Time Since Infection. J Infect Dis 2021; 224:1489-1499. [PMID: 34282461 PMCID: PMC8420633 DOI: 10.1093/infdis/jiab375] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2021] [Accepted: 07/19/2021] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces a complex antibody response that varies by orders of magnitude between individuals and over time. METHODS We developed a multiplex serological test for measuring antibodies to 5 SARS-CoV-2 antigens and the spike proteins of seasonal coronaviruses. We measured antibody responses in cohorts of hospitalized patients and healthcare workers followed for up to 11 months after symptoms. A mathematical model of antibody kinetics was used to quantify the duration of antibody responses. Antibody response data were used to train algorithms for estimating time since infection. RESULTS One year after symptoms, we estimate that 36% (95% range, 11%-94%) of anti-Spike immunoglobulin G (IgG) remains, 31% (95% range, 9%-89%) anti-RBD IgG remains, and 7% (1%-31%) of anti-nucleocapsid IgG remains. The multiplex assay classified previous infections into time intervals of 0-3 months, 3-6 months, and 6-12 months. This method was validated using data from a seroprevalence survey in France, demonstrating that historical SARS-CoV-2 transmission can be reconstructed using samples from a single survey. CONCLUSIONS In addition to diagnosing previous SARS-CoV-2 infection, multiplex serological assays can estimate the time since infection, which can be used to reconstruct past epidemics.
Collapse
Affiliation(s)
- Stéphane Pelleau
- Infectious Disease Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Paris, France
- Malaria: Parasites and Hosts Unit, Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France
| | - Tom Woudenberg
- Infectious Disease Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Paris, France
- Malaria: Parasites and Hosts Unit, Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France
| | - Jason Rosado
- Infectious Disease Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Paris, France
- Malaria: Parasites and Hosts Unit, Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France
- Sorbonne Université, Paris, France
| | - Françoise Donnadieu
- Infectious Disease Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Paris, France
- Malaria: Parasites and Hosts Unit, Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France
| | - Laura Garcia
- Infectious Disease Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Paris, France
- Malaria: Parasites and Hosts Unit, Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France
| | - Thomas Obadia
- Infectious Disease Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Paris, France
- Malaria: Parasites and Hosts Unit, Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France
- Hub de Bioinformatique et Biostatistique, Département Biologie Computationnelle, Institut Pasteur, Paris, France
| | - Soazic Gardais
- Malaria: Parasites and Hosts Unit, Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France
| | - Yasmine Elgharbawy
- Malaria: Parasites and Hosts Unit, Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France
| | - Aurelie Velay
- Centres Hospitaliers et Universitaires de Strasbourg, Laboratoire de Virologie, Strasbourg, France
- Université de Strasbourg, Inserm, Immuno-Rhumathologie moléculaire Unité Mixte de Recherche_S 1109, Strasbourg, France
| | - Maria Gonzalez
- Centres Hospitaliers et Universitaires de Strasbourg, Service de Pathologies Professionnelles, Strasbourg, France
| | | | | | | | - Charlotte Cockram
- Spatial Regulation of Genomes Unit, Department of Genomes and Genetics, Institut Pasteur, Paris, France
| | - Sarah Hélène Merkling
- Insect-Virus Interactions Unit, Department of Virology and French National Center for Scientific Research Unité Mixte de Recherche 2000, Institut Pasteur, Paris, France
| | - Annalisa Meola
- Structural Virology Unit, Department of Virology and French National Center for Scientific Research Unité Mixte de Recherche 3569, Institut Pasteur, Paris, France
| | - Solen Kerneis
- Equipe de Prévention du Risque Infectieux, Assistance Publique – Hôpitaux de Paris, Hôpital Bichat, Paris, France
- Université de Paris, Inserm, Infection Antimicrobials Modelling Evolution, Paris, France
- Epidemiology and Modelling of Antibiotic Evasion, Institut Pasteur, Paris, France
| | - Benjamin Terrier
- Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Assistance Publique Hôpitaux de Paris-Centre, Université de Paris, Paris,France
- Paris-Centre de Recherche Cardiovasculaire, Inserm U970, Paris, France
| | - Jerome de Seze
- Centre d’Investigation Clinique, Inserm CIC-1434, Strasbourg, France
| | - Delphine Planas
- Virus and Immunity Unit, Department of Virology, Institut Pasteur, Paris, France
| | - Olivier Schwartz
- Virus and Immunity Unit, Department of Virology, Institut Pasteur, Paris, France
| | - François Dejardin
- Production and Purification of Recombinant Proteins Technological Platform, Center for Technological Resources and Research, Institut Pasteur, Paris, France
| | - Stéphane Petres
- Production and Purification of Recombinant Proteins Technological Platform, Center for Technological Resources and Research, Institut Pasteur, Paris, France
| | | | | | - Laurence Arowas
- Investigation Clinique et Accès aux Ressources Biologiques, Center for Translational Research, Institut Pasteur, Paris, France
| | - Louise Perrin de Facci
- Investigation Clinique et Accès aux Ressources Biologiques, Center for Translational Research, Institut Pasteur, Paris, France
| | - Darragh Duffy
- Translational Immunology Laboratory, Institut Pasteur, Paris, France
| | - Clíona Ní Cheallaigh
- Department of Infectious Diseases, St James’s Hospital, Dublin, Ireland
- Department of Clinical Medicine, School of Medicine, Trinity Translational Medicine Institute, Trinity College, Dublin,Ireland
| | - Jean Dunne
- Department of Immunology, St James’s Hospital, Dublin, Ireland
- Department of Immunology, School of Medicine, Trinity College, Dublin,Ireland
| | - Niall Conlon
- Department of Immunology, St James’s Hospital, Dublin, Ireland
- Department of Immunology, School of Medicine, Trinity College, Dublin,Ireland
| | - Liam Townsend
- Department of Infectious Diseases, St James’s Hospital, Dublin, Ireland
- Department of Clinical Medicine, School of Medicine, Trinity Translational Medicine Institute, Trinity College, Dublin,Ireland
| | - Veasna Duong
- Virology Unit, Institut Pasteur du Cambodge, Institut Pasteur International Network, Phnom Penh,Cambodia
| | - Heidi Auerswald
- Virology Unit, Institut Pasteur du Cambodge, Institut Pasteur International Network, Phnom Penh,Cambodia
| | - Laurie Pinaud
- Epidemiology of Emerging Diseases Unit, Department of Global Health, Institut Pasteur, Paris, France
| | - Laura Tondeur
- Epidemiology of Emerging Diseases Unit, Department of Global Health, Institut Pasteur, Paris, France
| | - Marija Backovic
- Structural Virology Unit, Department of Virology and French National Center for Scientific Research Unité Mixte de Recherche 3569, Institut Pasteur, Paris, France
| | - Bruno Hoen
- Direction de la Recherche Médicale, Centre de Recherche Translationelle, Institut Pasteur, Paris, France
| | - Arnaud Fontanet
- Epidemiology of Emerging Diseases Unit, Department of Global Health, Institut Pasteur, Paris, France
- Conservatoire National des Arts et Métiers, Paris, France
| | - Ivo Mueller
- Malaria: Parasites and Hosts Unit, Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France
- Division of Population Health and Immunity, Walter and Eliza Hall Institute, Melbourne, Australia
- Department of Medical Biology, University of Melbourne, Melbourne, Australia
| | - Samira Fafi-Kremer
- Centres Hospitaliers et Universitaires de Strasbourg, Laboratoire de Virologie, Strasbourg, France
- Université de Strasbourg, Inserm, Immuno-Rhumathologie moléculaire Unité Mixte de Recherche_S 1109, Strasbourg, France
| | - Timothée Bruel
- Virus and Immunity Unit, Department of Virology, Institut Pasteur, Paris, France
- Vaccine Research Institute, Creteil, France
| | - Michael White
- Infectious Disease Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Paris, France
- Malaria: Parasites and Hosts Unit, Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France
| |
Collapse
|
9
|
Woudenberg T, Pelleau S, Anna F, Attia M, Donnadieu F, Gravet A, Lohmann C, Seraphin H, Guiheneuf R, Delamare C, Stefic K, Marlet J, Brochot E, Castelain S, Augereau O, Sibilia J, Dubos F, Meddour D, Guen CGL, Coste-Burel M, Imbert-Marcille BM, Chauvire-Drouard A, Schweitzer C, Gatin A, Lomazzi S, Joulié A, Haas H, Cantais A, Bertholon F, Chinazzo-Vigouroux MF, Abdallah MS, Arowas L, Charneau P, Hoen B, Demeret C, Werf SVD, Fontanet A, White M. Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France. EBioMedicine 2021; 70:103495. [PMID: 34304047 PMCID: PMC8299153 DOI: 10.1016/j.ebiom.2021.103495] [Citation(s) in RCA: 44] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2021] [Revised: 06/25/2021] [Accepted: 07/05/2021] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND Children are underrepresented in the COVID-19 pandemic and often experience milder disease than adolescents and adults. Reduced severity is possibly due to recent and more frequent seasonal human coronaviruses (HCoV) infections. We assessed the seroprevalence of SARS-CoV-2 and seasonal HCoV specific antibodies in a large cohort in north-eastern France. METHODS In this cross-sectional seroprevalence study, serum samples were collected from children and adults requiring hospital admission for non-COVID-19 between February and August 2020. Antibody responses to SARS-CoV-2 and seasonal HCoV (229E, HKU1, NL63, OC43) were assessed using a bead-based multiplex assay, Luciferase-Linked ImmunoSorbent Assay, and a pseudotype neutralisation assay. FINDINGS In 2,408 individuals, seroprevalence of SARS-CoV-2-specific antibodies was 7-8% with three different immunoassays. Antibody levels to seasonal HCoV increased substantially up to the age of 10. Antibody responses in SARS-CoV-2 seropositive individuals were lowest in adults 18-30 years. In SARS-CoV-2 seronegative individuals, we observed cross-reactivity between antibodies to the four HCoV and SARS-CoV-2 Spike. In contrast to other antibodies to SARS-CoV-2, specific antibodies to sub-unit 2 of Spike (S2) in seronegative samples were highest in children. Upon infection with SARS-CoV-2, antibody levels to Spike of betacoronavirus OC43 increased across the whole age spectrum. No SARS-CoV-2 seropositive individuals with low levels of antibodies to seasonal HCoV were observed. INTERPRETATION Our findings underline significant cross-reactivity between antibodies to SARS-CoV-2 and seasonal HCoV, but provide no significant evidence for cross-protective immunity to SARS-CoV-2 infection due to a recent seasonal HCoV infection. In particular, across all age groups we did not observe SARS-CoV-2 infected individuals with low levels of antibodies to seasonal HCoV. FUNDING This work was supported by the « URGENCE COVID-19 » fundraising campaign of Institut Pasteur, by the French Government's Investissement d'Avenir program, Laboratoire d'Excellence Integrative Biology of Emerging Infectious Diseases (Grant No. ANR-10-LABX-62-IBEID), and by the REACTing (Research & Action Emerging Infectious Diseases), and by the RECOVER project funded by the European Union's Horizon 2020 research and innovation programme under grant agreement No. 101003589, and by a grant from LabEx IBEID (ANR-10-LABX-62-IBEID).
Collapse
Affiliation(s)
- Tom Woudenberg
- Infectious Disease Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Paris, France; Malaria: Parasites and Hosts Unit, Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France.
| | - Stéphane Pelleau
- Infectious Disease Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Paris, France; Malaria: Parasites and Hosts Unit, Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France
| | - François Anna
- Molecular Virology and Vaccinoloy Unit, Department of Virology, Institut Pasteur, Paris, France
| | - Mikael Attia
- Molecular Genetics of RNA Viruses, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France
| | - Françoise Donnadieu
- Infectious Disease Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Paris, France; Malaria: Parasites and Hosts Unit, Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France
| | - Alain Gravet
- Laboratoire de Microbiologie, Groupement Hospitalier Régional de Mulhouse et Sud-Alsace, Mulhouse, France
| | - Caroline Lohmann
- Laboratoire de Microbiologie, Groupement Hospitalier Régional de Mulhouse et Sud-Alsace, Mulhouse, France
| | - Hélène Seraphin
- Centre Hospitalier Simone Veil de Beauvais, Beauvais, France
| | | | | | - Karl Stefic
- Service de Bactériologie-Virologie, Hôpital Bretonneau, CHRU de Tours, Tours, France
| | - Julien Marlet
- Service de Bactériologie-Virologie, Hôpital Bretonneau, CHRU de Tours, Tours, France
| | - Etienne Brochot
- Service de Virologie, CHU Amiens Picardie, UR 4294 AGIR UPJV, Amiens, France
| | - Sandrine Castelain
- Service de Virologie, CHU Amiens Picardie, UR 4294 AGIR UPJV, Amiens, France
| | - Olivier Augereau
- Service de Microbiologie, Hôpitaux Civils de Colmar, Colmar, France
| | - Jean Sibilia
- Laboratoire de Virologie, CHU de Strasbourg, Strasbourg, France
| | - François Dubos
- Univ. Lille, CHU Lille, Urgences pédiatriques et maladies infectieuses, Lille, France
| | - Damia Meddour
- Univ. Lille, CHU Lille, Urgences pédiatriques et maladies infectieuses, Lille, France
| | - Christèle Gras-Le Guen
- Urgences Pédiatrique et Pédiatrie Générale Hopital Mère Enfant CHU de Nantes, Nantes, France
| | | | | | | | - Cyril Schweitzer
- Hôpital d'Enfants, CHRU de Nancy, Vandoeuvre-Les-Nancy, France; EA 3450, DevAH, Université de Lorraine, Vandoeuvre Lès Nancy, France
| | - Amélie Gatin
- Pediatric Emergency Unit, Hôpital d'enfants, CHRU Nancy
| | | | - Aline Joulié
- Urgences pédiatriques et pédiatrie générale, hôpitaux pédiatriques CHU Lenval, Nice
| | - Hervé Haas
- Urgences pédiatriques et pédiatrie générale, hôpitaux pédiatriques CHU Lenval, Nice
| | - Aymeric Cantais
- Pediatric Emergency Department, Hospital University of St Etienne, France
| | | | | | | | - Laurence Arowas
- Investigation Clinique et Accès aux Ressources Biologiques (ICAReB), Center for Translational Research, Institut Pasteur, Paris, France
| | - Pierre Charneau
- Molecular Virology and Vaccinoloy Unit, Department of Virology, Institut Pasteur, Paris, France
| | - Bruno Hoen
- Direction de la recherche médicale, Institut Pasteur, Paris, France
| | - Caroline Demeret
- Molecular Genetics of RNA Viruses, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France
| | - Sylvie Van Der Werf
- Molecular Genetics of RNA Viruses, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France; National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France
| | - Arnaud Fontanet
- Emerging Diseases Epidemiology Unit, Department of Global Health, Institut Pasteur, Paris, France; PACRI Unit, Conservatoire National des Arts et Métiers, Paris, France.
| | - Michael White
- Infectious Disease Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Paris, France; Malaria: Parasites and Hosts Unit, Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France.
| |
Collapse
|
10
|
Norte AC, Boyer PH, Castillo-Ramirez S, Chvostáč M, Brahami MO, Rollins RE, Woudenberg T, Didyk YM, Derdakova M, Núncio MS, de Carvalho IL, Margos G, Fingerle V. The Population Structure of Borrelia lusitaniae Is Reflected by a Population Division of Its Ixodes Vector. Microorganisms 2021; 9:microorganisms9050933. [PMID: 33925391 PMCID: PMC8145215 DOI: 10.3390/microorganisms9050933] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Revised: 04/19/2021] [Accepted: 04/21/2021] [Indexed: 01/29/2023] Open
Abstract
Populations of vector-borne pathogens are shaped by the distribution and movement of vector and reservoir hosts. To study what impact host and vector association have on tick-borne pathogens, we investigated the population structure of Borrelia lusitaniae using multilocus sequence typing (MLST). Novel sequences were acquired from questing ticks collected in multiple North African and European locations and were supplemented by publicly available sequences at the Borrelia Pubmlst database (accessed on 11 February 2020). Population structure of B. lusitaniae was inferred using clustering and network analyses. Maximum likelihood phylogenies for two molecular tick markers (the mitochondrial 16S rRNA locus and a nuclear locus, Tick-receptor of outer surface protein A, trospA) were used to confirm the morphological species identification of collected ticks. Our results confirmed that B. lusitaniae does indeed form two distinguishable populations: one containing mostly European samples and the other mostly Portuguese and North African samples. Of interest, Portuguese samples clustered largely based on being from north (European) or south (North African) of the river Targus. As two different Ixodes species (i.e., I. ricinus and I. inopinatus) may vector Borrelia in these regions, reference samples were included for I. inopinatus but did not form monophyletic clades in either tree, suggesting some misidentification. Even so, the trospA phylogeny showed a monophyletic clade containing tick samples from Northern Africa and Portugal south of the river Tagus suggesting a population division in Ixodes on this locus. The pattern mirrored the clustering of B. lusitaniae samples, suggesting a potential co-evolution between tick and Borrelia populations that deserve further investigation.
Collapse
Affiliation(s)
- Ana Cláudia Norte
- MARE-Marine and Environmental Sciences Centre, Department of Life Sciences, University of Coimbra, 3000-456 Coimbra, Portugal;
- Centre for Vector and Infectious Diseases Research, National Institute of Health Doutor Ricardo Jorge, Águas de Moura, 2965-575 Setúbal, Portugal; (M.S.N.); (I.L.d.C.)
| | - Pierre H. Boyer
- CHRU Strasbourg, UR7290 Lyme Borreliosis Group, ITI InnoVec, Fédération de Médecine Translationnelle de Strasbourg, Institut de Bactériologie, University of Strasbourg, 3 rue Koeberlé, 67000 Strasbourg, France;
| | - Santiago Castillo-Ramirez
- Programa de Genómica Evolutiva, Centro de Ciencias Genómicas, Universidad Nacional Autónoma de México, Apartado Postal 565-A, Cuernavaca, CP 62210, Mexico;
| | - Michal Chvostáč
- Institute of Zoology, Slovak Academy of Sciences, 84506 Bratislava, Slovakia; (M.C.); (Y.M.D.); (M.D.)
| | - Mohand O. Brahami
- Laboratory of Ecology and Biology of Terrestrial Ecosystems, Faculty Biological and Agronomic Sciences, University Mouloud Mammeri, 15000 Tizi-Ouzou, Algeria;
| | - Robert E. Rollins
- Division of Evolutionary Biology, LMU Munich, Faculty of Biology, Grosshaderner Strasse 2, 82152 Planegg-Martinsried, Germany;
| | - Tom Woudenberg
- National Reference Center for Borrelia, Bavarian Health and Food Safety Authority, 85764 Oberschleissheim, Germany; (T.W.); (V.F.)
| | - Yuliya M. Didyk
- Institute of Zoology, Slovak Academy of Sciences, 84506 Bratislava, Slovakia; (M.C.); (Y.M.D.); (M.D.)
- Department of Acarology, I. I. Schmalhausen Institute of Zoology, National Academy of Sciences of Ukraine, B. Khmelnytskogo 15, 01030 Kyiv, Ukraine
| | - Marketa Derdakova
- Institute of Zoology, Slovak Academy of Sciences, 84506 Bratislava, Slovakia; (M.C.); (Y.M.D.); (M.D.)
| | - Maria Sofia Núncio
- Centre for Vector and Infectious Diseases Research, National Institute of Health Doutor Ricardo Jorge, Águas de Moura, 2965-575 Setúbal, Portugal; (M.S.N.); (I.L.d.C.)
- Environmental Health Institute, Medicine Faculty, University of Lisbon, 1649-026 Lisbon, Portugal
| | - Isabel Lopes de Carvalho
- Centre for Vector and Infectious Diseases Research, National Institute of Health Doutor Ricardo Jorge, Águas de Moura, 2965-575 Setúbal, Portugal; (M.S.N.); (I.L.d.C.)
- Environmental Health Institute, Medicine Faculty, University of Lisbon, 1649-026 Lisbon, Portugal
| | - Gabriele Margos
- National Reference Center for Borrelia, Bavarian Health and Food Safety Authority, 85764 Oberschleissheim, Germany; (T.W.); (V.F.)
- Correspondence: or ; Tel.: +49-9131-6808-5883
| | - Volker Fingerle
- National Reference Center for Borrelia, Bavarian Health and Food Safety Authority, 85764 Oberschleissheim, Germany; (T.W.); (V.F.)
| |
Collapse
|
11
|
Böhm S, Woudenberg T, Chen D, Marosevic DV, Böhmer MM, Hansen L, Wallinga J, Sing A, Katz K. Epidemiology and transmission characteristics of early COVID-19 cases, 20 January-19 March 2020, in Bavaria, Germany. Epidemiol Infect 2021; 149:e65. [PMID: 33650470 PMCID: PMC7985897 DOI: 10.1017/s0950268821000510] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2020] [Revised: 01/13/2021] [Accepted: 02/25/2021] [Indexed: 01/18/2023] Open
Abstract
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) led to a significant disease burden and disruptions in health systems. We describe the epidemiology and transmission characteristics of early coronavirus disease 2019 (COVID-19) cases in Bavaria, Germany. Cases were reverse transcription polymerase chain reaction (RT-PCR)-confirmed SARS-CoV-2 infections, reported from 20 January-19 March 2020. The incubation period was estimated using travel history and date of symptom onset. To estimate the serial interval, we identified pairs of index and secondary cases. By 19 March, 3546 cases were reported. A large proportion was exposed abroad (38%), causing further local transmission. Median incubation period of 256 cases with exposure abroad was 3.8 days (95%CI: 3.5-4.2). For 95% of infected individuals, symptom onset occurred within 10.3 days (95%CI: 9.1-11.8) after exposure. The median serial interval, using 53 pairs, was 3.5 days (95%CI: 3.0-4.2; mean: 3.9, s.d.: 2.2). Travellers returning to Germany had an important influence on the spread of SARS-CoV-2 infections in Bavaria in early 2020. Especially in times of low incidence, public health agencies should identify holiday destinations, and areas with ongoing local transmission, to monitor potential importation of SARS-CoV-2 infections. Travellers returning from areas with ongoing community transmission should be advised to quarantine to prevent re-introductions of COVID-19.
Collapse
Affiliation(s)
- S. Böhm
- Bavarian Health and Food Safety Authority, Oberschleissheim, Germany
- ECDC Fellowship Programme, Field Epidemiology path (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
- Postgraduate Training for Applied Epidemiology (PAE), Robert Koch Institute, Berlin, Germany
| | - T. Woudenberg
- Bavarian Health and Food Safety Authority, Oberschleissheim, Germany
- ECDC Fellowship Programme, Field Epidemiology path (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
| | - D. Chen
- National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands
| | - D. V. Marosevic
- Bavarian Health and Food Safety Authority, Oberschleissheim, Germany
| | - M. M. Böhmer
- Bavarian Health and Food Safety Authority, Oberschleissheim, Germany
- Institute of Social Medicine and Health Systems Research, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany
| | - L. Hansen
- ECDC Fellowship Programme, Field Epidemiology path (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
- National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands
| | - J. Wallinga
- National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands
- Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Netherlands
| | - A. Sing
- Bavarian Health and Food Safety Authority, Oberschleissheim, Germany
| | - K. Katz
- Bavarian Health and Food Safety Authority, Oberschleissheim, Germany
| |
Collapse
|
12
|
Böhmer MM, Buchholz U, Corman VM, Hoch M, Katz K, Marosevic DV, Böhm S, Woudenberg T, Ackermann N, Konrad R, Eberle U, Treis B, Dangel A, Bengs K, Fingerle V, Berger A, Hörmansdorfer S, Ippisch S, Wicklein B, Grahl A, Pörtner K, Muller N, Zeitlmann N, Boender TS, Cai W, Reich A, an der Heiden M, Rexroth U, Hamouda O, Schneider J, Veith T, Mühlemann B, Wölfel R, Antwerpen M, Walter M, Protzer U, Liebl B, Haas W, Sing A, Drosten C, Zapf A. Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series. Lancet Infect Dis 2020; 20:920-928. [PMID: 32422201 PMCID: PMC7228725 DOI: 10.1016/s1473-3099(20)30314-5] [Citation(s) in RCA: 281] [Impact Index Per Article: 70.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/12/2020] [Revised: 04/09/2020] [Accepted: 04/09/2020] [Indexed: 12/20/2022]
Abstract
BACKGROUND In December, 2019, the newly identified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, causing COVID-19, a respiratory disease presenting with fever, cough, and often pneumonia. WHO has set the strategic objective to interrupt spread of SARS-CoV-2 worldwide. An outbreak in Bavaria, Germany, starting at the end of January, 2020, provided the opportunity to study transmission events, incubation period, and secondary attack rates. METHODS A case was defined as a person with SARS-CoV-2 infection confirmed by RT-PCR. Case interviews were done to describe timing of onset and nature of symptoms and to identify and classify contacts as high risk (had cumulative face-to-face contact with a confirmed case for ≥15 min, direct contact with secretions or body fluids of a patient with confirmed COVID-19, or, in the case of health-care workers, had worked within 2 m of a patient with confirmed COVID-19 without personal protective equipment) or low risk (all other contacts). High-risk contacts were ordered to stay at home in quarantine for 14 days and were actively followed up and monitored for symptoms, and low-risk contacts were tested upon self-reporting of symptoms. We defined fever and cough as specific symptoms, and defined a prodromal phase as the presence of non-specific symptoms for at least 1 day before the onset of specific symptoms. Whole genome sequencing was used to confirm epidemiological links and clarify transmission events where contact histories were ambiguous; integration with epidemiological data enabled precise reconstruction of exposure events and incubation periods. Secondary attack rates were calculated as the number of cases divided by the number of contacts, using Fisher's exact test for the 95% CIs. FINDINGS Patient 0 was a Chinese resident who visited Germany for professional reasons. 16 subsequent cases, often with mild and non-specific symptoms, emerged in four transmission generations. Signature mutations in the viral genome occurred upon foundation of generation 2, as well as in one case pertaining to generation 4. The median incubation period was 4·0 days (IQR 2·3-4·3) and the median serial interval was 4·0 days (3·0-5·0). Transmission events were likely to have occurred presymptomatically for one case (possibly five more), at the day of symptom onset for four cases (possibly five more), and the remainder after the day of symptom onset or unknown. One or two cases resulted from contact with a case during the prodromal phase. Secondary attack rates were 75·0% (95% CI 19·0-99·0; three of four people) among members of a household cluster in common isolation, 10·0% (1·2-32·0; two of 20) among household contacts only together until isolation of the patient, and 5·1% (2·6-8·9; 11 of 217) among non-household, high-risk contacts. INTERPRETATION Although patients in our study presented with predominately mild, non-specific symptoms, infectiousness before or on the day of symptom onset was substantial. Additionally, the incubation period was often very short and false-negative tests occurred. These results suggest that although the outbreak was controlled, successful long-term and global containment of COVID-19 could be difficult to achieve. FUNDING All authors are employed and all expenses covered by governmental, federal state, or other publicly funded institutions.
Collapse
Affiliation(s)
- Merle M Böhmer
- Bavarian Health and Food Safety Authority, Oberschleissheim, Germany; Institute of Social Medicine and Health Systems Research, Otto-von-Guericke-University, Magdeburg, Germany.
| | | | - Victor M Corman
- Institute of Virology, Charité University Medicine, Berlin, Germany,German Center for Infection Research, Partner Site Munich and Associated Partner Site Charité, Berlin, Germany
| | - Martin Hoch
- Bavarian Health and Food Safety Authority, Oberschleissheim, Germany
| | - Katharina Katz
- Bavarian Health and Food Safety Authority, Oberschleissheim, Germany
| | | | - Stefanie Böhm
- Bavarian Health and Food Safety Authority, Oberschleissheim, Germany,Postgraduate Training for Applied Epidemiology, Berlin, Germany,ECDC Fellowship Programme, Field Epidemiology Path, European Centre for Disease Prevention and Control, Stockholm, Sweden
| | - Tom Woudenberg
- Bavarian Health and Food Safety Authority, Oberschleissheim, Germany,ECDC Fellowship Programme, Field Epidemiology Path, European Centre for Disease Prevention and Control, Stockholm, Sweden
| | | | - Regina Konrad
- Bavarian Health and Food Safety Authority, Oberschleissheim, Germany
| | - Ute Eberle
- Bavarian Health and Food Safety Authority, Oberschleissheim, Germany
| | - Bianca Treis
- Bavarian Health and Food Safety Authority, Oberschleissheim, Germany
| | - Alexandra Dangel
- Bavarian Health and Food Safety Authority, Oberschleissheim, Germany
| | - Katja Bengs
- Bavarian Health and Food Safety Authority, Oberschleissheim, Germany
| | - Volker Fingerle
- Bavarian Health and Food Safety Authority, Oberschleissheim, Germany
| | - Anja Berger
- Bavarian Health and Food Safety Authority, Oberschleissheim, Germany
| | | | - Siegfried Ippisch
- Bavarian Health and Food Safety Authority, Oberschleissheim, Germany
| | - Bernd Wicklein
- Bavarian Health and Food Safety Authority, Oberschleissheim, Germany
| | - Andreas Grahl
- Bavarian Health and Food Safety Authority, Oberschleissheim, Germany
| | - Kirsten Pörtner
- Postgraduate Training for Applied Epidemiology, Berlin, Germany,ECDC Fellowship Programme, Field Epidemiology Path, European Centre for Disease Prevention and Control, Stockholm, Sweden
| | - Nadine Muller
- Postgraduate Training for Applied Epidemiology, Berlin, Germany,ECDC Fellowship Programme, Field Epidemiology Path, European Centre for Disease Prevention and Control, Stockholm, Sweden
| | | | - T Sonia Boender
- Postgraduate Training for Applied Epidemiology, Berlin, Germany,ECDC Fellowship Programme, Field Epidemiology Path, European Centre for Disease Prevention and Control, Stockholm, Sweden
| | - Wei Cai
- Robert Koch Institute, Berlin, Germany
| | | | | | | | | | - Julia Schneider
- Institute of Virology, Charité University Medicine, Berlin, Germany
| | - Talitha Veith
- Institute of Virology, Charité University Medicine, Berlin, Germany
| | - Barbara Mühlemann
- Institute of Virology, Charité University Medicine, Berlin, Germany,German Center for Infection Research, Partner Site Munich and Associated Partner Site Charité, Berlin, Germany
| | - Roman Wölfel
- German Center for Infection Research, Partner Site Munich and Associated Partner Site Charité, Berlin, Germany,Bundeswehr Institute of Microbiology, Munich, Germany
| | - Markus Antwerpen
- German Center for Infection Research, Partner Site Munich and Associated Partner Site Charité, Berlin, Germany,Bundeswehr Institute of Microbiology, Munich, Germany
| | - Mathias Walter
- German Center for Infection Research, Partner Site Munich and Associated Partner Site Charité, Berlin, Germany,Bundeswehr Institute of Microbiology, Munich, Germany
| | - Ulrike Protzer
- German Center for Infection Research, Partner Site Munich and Associated Partner Site Charité, Berlin, Germany,Institute of Virology, Technical University Munich, Munich, Germany
| | - Bernhard Liebl
- Bavarian Health and Food Safety Authority, Oberschleissheim, Germany,Ludwig-Maximilians University, Munich, Germany
| | | | - Andreas Sing
- Bavarian Health and Food Safety Authority, Oberschleissheim, Germany,Ludwig-Maximilians University, Munich, Germany
| | - Christian Drosten
- Institute of Virology, Charité University Medicine, Berlin, Germany; German Center for Infection Research, Partner Site Munich and Associated Partner Site Charité, Berlin, Germany.
| | - Andreas Zapf
- Bavarian Health and Food Safety Authority, Oberschleissheim, Germany
| |
Collapse
|
13
|
van Dam A, Woudenberg T, de Melker H, Wallinga J, Hahné S. Effect of vaccination on severity and infectiousness of measles during an outbreak in the Netherlands, 2013-2014. Epidemiol Infect 2020; 148:e81. [PMID: 32200773 PMCID: PMC7189345 DOI: 10.1017/s0950268820000692] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2019] [Revised: 01/28/2020] [Accepted: 03/04/2020] [Indexed: 11/17/2022] Open
Abstract
An outbreak of measles in the Netherlands in 2013-2014 provided an opportunity to assess the effect of MMR vaccination on severity and infectiousness of measles.Measles is notifiable in the Netherlands. We used information on vaccination, hospitalisation, complications, and most likely source(s) of infection from cases notified during the outbreak. When a case was indicated as a likely source for at least one other notified case, we defined it as infectious. We estimated the age-adjusted effect of vaccination on severity and infectiousness with logistic regression.Of 2676 notified cases, 2539 (94.9%) were unvaccinated, 121 (4.5%) were once-vaccinated and 16 (0.6%) were at least twice-vaccinated; 328 (12.3%) cases were reported to have complications and 172 (6.4%) cases were hospitalised. Measles in twice-vaccinated cases led less often to complications and/or hospitalisation than measles in unvaccinated cases (0% and 14.5%, respectively, aOR 0.1 (95% CI 0-0.89), P = 0.03). Of unvaccinated, once-vaccinated and twice-vaccinated cases, respectively, 194 (7.6%), seven (5.1%) and 0 (0%) were infectious. These differences were not statistically significant (P > 0.05).Our findings suggest a protective effect of vaccination on the occurrence of complications and/or hospitalisation as a result of measles and support the WHO recommendation of a two-dose MMR vaccination schedule.
Collapse
Affiliation(s)
- A.S.G. van Dam
- Department of infectious diseases, GGD Hart voor Brabant, ‘s-Hertogenbosch, The Netherlands
- National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
- European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
| | - T. Woudenberg
- National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| | - H.E. de Melker
- National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| | - J. Wallinga
- National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
- Leiden University Medical Center, Leiden, The Netherlands
| | - S.J.M. Hahné
- National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| |
Collapse
|
14
|
Woudenberg T, van Binnendijk R, Veldhuijzen I, Woonink F, Ruijs H, van der Klis F, Kerkhof J, de Melker H, de Swart R, Hahné S. Additional Evidence on Serological Correlates of Protection against Measles: An Observational Cohort Study among Once Vaccinated Children Exposed to Measles. Vaccines (Basel) 2019; 7:vaccines7040158. [PMID: 31652599 PMCID: PMC6963647 DOI: 10.3390/vaccines7040158] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2019] [Revised: 10/14/2019] [Accepted: 10/16/2019] [Indexed: 12/11/2022] Open
Abstract
To assess correlates of protection against measles and against subclinical measles virus (MV) infection, we recruited once-vaccinated children from geographic regions associated with increased MV circulation and/or at schools with low vaccination coverage in the Netherlands. Paired blood samples were collected shortly after onset of the measles outbreak and after the outbreak. A questionnaire was used to document the likelihood of exposure to MV and occurrence of measles-like symptoms. All blood samples were tested for MV-specific antibodies with five different assays. Correlates of protection were assessed by considering the lowest neutralizing antibody levels in children without MV infection, and by ROC analyses. Among 91 participants, two seronegative children (2%) developed measles, and an additional 19 (23%) experienced subclinical MV infection. The correlate of protection against measles was lower than 0.345 IU/mL. We observed a decreasing attack rate of subclinical MV infection with increasing levels of specific antibodies until 2.1 IU/mL, above which no subclinical MV infections were detected. The ROC analyses found a correlate of protection of 1.71 IU/mL (95% CI 1.01–2.11) for subclinical MV infection. Our correlates of protection were consistent with previous estimates. This information supports the analyses of serosurveys to detect immunity gaps that require targeted intervention strategies.
Collapse
Affiliation(s)
- Tom Woudenberg
- Centre for Infectious Disease Control, Netherlands Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoek 9, 3720 MA Bilthoven, The Netherlands.
| | - Rob van Binnendijk
- Centre for Infectious Disease Control, Netherlands Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoek 9, 3720 MA Bilthoven, The Netherlands.
| | - Irene Veldhuijzen
- Centre for Infectious Disease Control, Netherlands Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoek 9, 3720 MA Bilthoven, The Netherlands.
| | - Frits Woonink
- Public Health Service, Region Utrecht, De Dreef 5, 3706 BR Zeist, The Netherlands.
| | - Helma Ruijs
- Centre for Infectious Disease Control, Netherlands Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoek 9, 3720 MA Bilthoven, The Netherlands.
| | - Fiona van der Klis
- Centre for Infectious Disease Control, Netherlands Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoek 9, 3720 MA Bilthoven, The Netherlands.
| | - Jeroen Kerkhof
- Centre for Infectious Disease Control, Netherlands Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoek 9, 3720 MA Bilthoven, The Netherlands.
| | - Hester de Melker
- Centre for Infectious Disease Control, Netherlands Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoek 9, 3720 MA Bilthoven, The Netherlands.
| | - Rik de Swart
- Department of Viroscience, Erasmus MC, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
| | - Susan Hahné
- Centre for Infectious Disease Control, Netherlands Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoek 9, 3720 MA Bilthoven, The Netherlands.
| |
Collapse
|
15
|
Woudenberg T, van der Maas NAT, Knol MJ, de Melker H, van Binnendijk RS, Hahné SJM. Effectiveness of Early Measles, Mumps, and Rubella Vaccination Among 6-14-Month-Old Infants During an Epidemic in the Netherlands: An Observational Cohort Study. J Infect Dis 2017; 215:1181-1187. [PMID: 28368471 DOI: 10.1093/infdis/jiw586] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2016] [Accepted: 12/02/2016] [Indexed: 11/13/2022] Open
Abstract
Background Routinely, the first measles, mumps, and rubella (MMR) vaccine dose is given at 14 months of age in the Netherlands. However, during a measles epidemic in 2013-2014, MMR vaccination was also offered to 6-14-month-olds in municipalities with <90% MMR vaccination coverage. We studied the effectiveness of the early MMR vaccination schedule. Methods Parents of all infants targeted for early MMR vaccination were asked to participate. When parent(s) suspected measles, their infant's saliva was tested for measles-specific antibodies. The vaccine effectiveness (VE) against laboratory-confirmed and self-reported measles was estimated using Cox regression, with VE calculated as 1 minus the hazard ratio. Results Three vaccinated and 10 unvaccinated laboratory-confirmed cases occurred over observation times of 106631 and 23769 days, respectively. The unadjusted VE against laboratory-confirmed measles was 94% (95% confidence interval [CI], 79%-98%). After adjustment for religion and sibling's vaccination status, the VE decreased to 71% (-72%-95%). For self-reported measles, the unadjusted and adjusted VE was 67% (40%-82%) and 43% (-12%-71%), respectively. Conclusions Infants vaccinated between 6 and 14 months of age had a lower risk of measles than unvaccinated infants. However, part of the effect was caused by herd immunity, since vaccinated infants were more likely to be surrounded by other vaccinated individuals.
Collapse
Affiliation(s)
| | | | | | | | - Rob S van Binnendijk
- Center for Infectious Diseases Research, Diagnostics, and Screening, National Institute for Public Health and the Environment, Bilthoven, the Netherlands
| | | |
Collapse
|
16
|
Woudenberg T, van Binnendijk RS, Sanders EAM, Wallinga J, de Melker HE, Ruijs WLM, Hahné SJM. Large measles epidemic in the Netherlands, May 2013 to March 2014: changing epidemiology. ACTA ACUST UNITED AC 2017; 22:30443. [PMID: 28128092 PMCID: PMC5322286 DOI: 10.2807/1560-7917.es.2017.22.3.30443] [Citation(s) in RCA: 46] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2016] [Accepted: 10/21/2016] [Indexed: 11/20/2022]
Abstract
Since the early 1990s, the Netherlands has experienced several large measles epidemics, in 1992–94, 1999–2000 and in 2013–14. These outbreaks mainly affected orthodox Protestants, a geographically clustered population with overall lower measles-mumps-rubella first dose (MMR-1) vaccination coverage (60%) than the rest of the country (> 95%). In the 2013–14 epidemic described here, which occurred between 27 May 2013 and 12 March 2014, 2,700 cases were reported. Several control measures were implemented including MMR vaccination for 6–14-month-olds and recommendations to reduce the risk in healthcare workers. The vast majority of reported cases were unvaccinated (94%, n = 2,539), mostly for religious reasons (84%, n = 2,135). The median age in the epidemic was 10 years, 4 years older than in the previous epidemic in 1999–2000. A likely explanation is that the inter-epidemic interval before the 2013–2014 epidemic was longer than the interval before the 1999–2000 epidemic. The size of the unvaccinated orthodox Protestant community is insufficient to allow endemic transmission of measles in the Netherlands. However, large epidemics are expected in the future, which is likely to interfere with measles elimination in the Netherlands and elsewhere.
Collapse
Affiliation(s)
- Tom Woudenberg
- National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.,University Medical Center Utrecht, Utrecht, the Netherlands
| | - Rob S van Binnendijk
- National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
| | - Elisabeth A M Sanders
- National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.,University Medical Center Utrecht, Utrecht, the Netherlands
| | - Jacco Wallinga
- National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.,Leiden University Medical Center, Leiden, the Netherlands
| | - Hester E de Melker
- National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
| | - Wilhelmina L M Ruijs
- National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
| | - Susan J M Hahné
- National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
| |
Collapse
|
17
|
Suijkerbuijk AWM, Woudenberg T, Hahné SJM, Nic Lochlainn L, de Melker HE, Ruijs WLM, Lugnér AK. Economic Costs of Measles Outbreak in the Netherlands, 2013-2014. Emerg Infect Dis 2016; 21:2067-9. [PMID: 26488199 PMCID: PMC4622243 DOI: 10.3201/eid2111.150410] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
In 2013 and 2014, the Netherlands experienced a measles outbreak in orthodox Protestant communities with low measles–mumps–rubella vaccination coverage. Assessing total outbreak costs is needed for public health outbreak preparedness and control. Total costs of this outbreak were an estimated $4.7 million.
Collapse
|
18
|
van der Maas NAT, Woudenberg T, Hahné SJM, de Melker HE. Tolerability of Early Measles-Mumps-Rubella Vaccination in Infants Aged 6-14 Months During a Measles Outbreak in The Netherlands in 2013-2014. J Infect Dis 2015; 213:1466-71. [PMID: 26690343 PMCID: PMC4813742 DOI: 10.1093/infdis/jiv756] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2015] [Accepted: 12/14/2015] [Indexed: 12/12/2022] Open
Abstract
Background. In 2013–2014, a measles outbreak spread through the Netherlands. To protect young infants, measles-mumps-rubella (MMR) vaccination was offered to those aged 6–14 months in municipalities with routine first-dose MMR vaccine coverage of <90%. We assessed the tolerability of this early administration of MMR vaccine. Methods. After study entry (n = 1866), parents of eligible infants (n = 10 097) completed a questionnaire (n = 1304). For infants who received an early MMR vaccine dose (n = 962), we asked for information about adverse events (AEs) associated with the dose. AE frequencies were compared between infants aged 6–8, 9–11, and 12–14 months. Using multivariable logistic regression, we assessed the association between the risk of AEs and age at early MMR vaccination. Results. The response rate was 13%. Parents of 59 infants (6.1%) and 350 infants (36.4%) who received early MMR vaccination reported local and systemic AEs, respectively. Parents of infants vaccinated at 6–8 months of age reported systemic AEs less frequently (32%) than parents of children vaccinated at 9–11 months (45%) and 12–14 months (43%) of age (P = <.001). For local AEs, there were no differences (5%, 7%, and 10%, respectively; P = .08). Compared with vaccination at 6 months, all older infants except those aged 14 months showed an increased risk for any AE and for systemic AEs starting 5–12 days after vaccination. Conclusions. Early MMR vaccination is well tolerated, with the lowest AE frequencies found in infants aged 6–8 months. It is a safe intervention for protecting young infants against measles.
Collapse
Affiliation(s)
- Nicoline A T van der Maas
- Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands
| | - T Woudenberg
- Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands
| | - S J M Hahné
- Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands
| | - H E de Melker
- Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands
| |
Collapse
|
19
|
DiCesare J, Grossman B, Katz E, Picozza E, Ragusa R, Woudenberg T. A high-sensitivity electrochemiluminescence-based detection system for automated PCR product quantitation. Biotechniques 1993; 15:152-7. [PMID: 8363832] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
A high-sensitivity nonisotopic system has been developed for post-PCR product detection. The probe-based detection system exploits a chemiluminescent reaction that takes place on the electrode surface in an electrochemical cell. The detection system incorporates a biotin-streptavidin capture reaction onto a solid support that permits fast post-PCR product detection at the attomole level. The system precision is within 5% relative standard deviation over a linear dynamic range of greater than three orders of magnitude. In this paper, the principles and features of the electrochemiluminescent-based detection system, together with its application to PCR product quantitation, are described in detail.
Collapse
Affiliation(s)
- J DiCesare
- Perkin-Elmer Corporation, Wilton, CT 06897
| | | | | | | | | | | |
Collapse
|
20
|
Haff L, Atwood JG, DiCesare J, Katz E, Picozza E, Williams JF, Woudenberg T. A high-performance system for automation of the polymerase chain reaction. Biotechniques 1991; 10:102-3, 106-12. [PMID: 2003915] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
A high-performance PCR system has been developed which reduces the time required for PCR, increases the throughput, reduces reagent consumption and ensures reproducibility of amplification. Integration of sophisticated temperature control with optimally designed vessels has resulted in an amplification system which produces unique benefits. These include rapid amplification, the elimination of the need for oil, even for small volumes, and a microplate format which provides liquid handling automation benefits.
Collapse
Affiliation(s)
- L Haff
- Perkin-Elmer Corporation, Norwalk, CT 06859-0251
| | | | | | | | | | | | | |
Collapse
|